ALX Oncology (ALXO) vs Organogenesis (ORGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ALX Oncology (ALXO) has outperformed Organogenesis (ORGO) over the past year, losing 35.6% versus a loss of 68.1%. Over five years, ORGO leads with a -88.2% price change compared with -97.9% for ALXO. ALX Oncology is the larger company by market cap ($172.8 million vs $166.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | ORGO |
|---|---|---|
| Share price | $1.25 | $1.29 |
| Market cap | $172.85M | $165.99M |
| 1-day change | +5.93% | +0.78% |
| YTD return | +10.62% | -75.10% |
| 1-year return | -35.57% | -68.07% |
| 5-year return | -97.88% | -88.22% |
| EPS (TTM) | $-1.20 | $-0.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.66 | $7.08 |
| 52-week low | $1.05 | $1.25 |
| Distance from 52-week high | -53.01% | -81.77% |
| Analyst consensus | none | none |
| Avg. price target upside | +268.00% | +55.04% |
| Average volume | 1.04M | 770.59K |
| Shares outstanding | 138.28M | 128.67M |
| Employees | 48 | 854 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALXO has outperformed ORGO by 32.5 percentage points over the past year.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Organogenesis
ORGO stock →Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature.
Health Care · Biotechnology: Pharmaceutical Preparations · 854 employees
ALXO vs ORGO FAQ
Which is bigger, ALX Oncology or Organogenesis?
ALX Oncology (ALXO) is larger, with a market capitalization of $172.85M compared with $165.99M for Organogenesis (ORGO).
Which stock has performed better over the past year, ALXO or ORGO?
ALXO returned -35.57% over the past 12 months, compared with -68.07% for ORGO (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and Organogenesis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.